Evaluating Cybin—now operating commercially as Helus Pharma—as a stock investment involves weighing its pioneering work in novel psychiatric therapeutics against the high volatility and speculative nature of early-stage biotechnology equities. The company holds breakthrough therapy designations and advanced clinical pipelines targeting severe mental health conditions, which offers significant upside potential if its drug candidates successfully secure regulatory approval. However, because the firm is still navigating expensive clinical trials and has not yet achieved sustained commercial profitability, it carries a high risk profile suited primarily for aggressive investors comfortable with biotechnology sector volatility.